Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Virpax Pharmaceuticals Inc (NQ: VRPX )

0.4630 -0.0170 (-3.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Virpax Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Virpax Pharmaceuticals Stock Is Trading Higher Today
Virpax Pharmaceuticals (NASDAQ: VRPX) is trading higher after the company announced it entered into a commercial manufacturing and supply agreement with Seqens. The agreement with... 
Via Benzinga
45 Stocks Moving In Thursday's Mid-Day Session
Gainers Blue Water Acquisition Corp. (NASDAQ: BLUW) shares climbed 57% to $16.41. Blue Water Acquisition is expected to hold a special meeting of its stockholders on Friday,... 
Via Benzinga
Virpax Announces MMS019 Manufacturing and Supply Agreement
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
54 Biggest Movers From Yesterday
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares jumped 202.8% to settle at $46.33 on Wednesday after gaining over 11% on Tuesday. Regencell Bioscience recently... 
Via Benzinga
36 Stocks Moving In Wednesday's Mid-Day Session
Gainers Locust Walk Acquisition Corp. (NASDAQ: LWAC) shares jumped 188% to $25.34 after the company announced stockholders approved a business combination with eFFECTOR... 
Via Benzinga
The Week Ahead In Biotech: Cara FDA Decision, Ascendis Earnings, Aileron Data Presentation And More
Biotech stocks swayed back and forth before ending the week lower. With earnings news dying down and an empty initial public offerings calendar, it was broader market cues,... 
Via Benzinga
Exposures Product Safety
22 Stocks Moving in Friday's Pre-Market Session
Gainers GeoVax Labs, Inc.. (NASDAQ: GOVX) shares rose 72.1% to $7.40 in pre-market trading after the company announced it presented COVID-19 vaccine data at the European Society... 
Via Benzinga
Exposures COVID-19
38 Stocks Moving In Thursday's Mid-Day Session
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares jumped 141% to $1.7950 after dropping 12% on Wednesday. Sonnet BioTherapeutics recently reported its financial... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares climbed 63.7% to close at $1.22 on Thursday after dropping 12% on Wednesday. Sonnet BioTherapeutics recently... 
Via Benzinga
21 Stocks Moving in Thursday's Pre-Market Session
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares rose 86.5% to $1.39 in pre-market trading after dropping 12% on Wednesday. Sonnet BioTherapeutics recently... 
Via Benzinga
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
46 Biggest Movers From Yesterday
Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares climbed 189.5% to close at $9.90 on Wednesday after surging over 15% on Tuesday. SGOCO Group, Ltd. (NASDAQ: SGOC) surged 67... 
Via Benzinga
VRPX Stock: What Investors Are Saying About Virpax Pharma as Shares Continue to Fly
Shares of VRPX stock continue to blow up on Wednesday after Virpax Pharmaceuticals' massive business announcement on Tuesday. 
Via InvestorPlace
Exposures Product Safety
Mid-Afternoon Market Update: Crude Oil Down 1.5%; Tuya Shares Plummet
Toward the end of trading Wednesday, the Dow traded down 0.27% to 35,249.25 while the NASDAQ rose 0.06% to 14,664.67. The S&P also fell, dropping 0.21% to 4,438.73. The U.S.... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Mid-Day Market Update: Alcon Rises Following Q2 Results; NexPoint Real Estate Finance Shares Slide
Midway through trading Wednesday, the Dow traded down 0.12% to 35,299.82 while the NASDAQ fell 0.01% to 14,654.93. The S&P also fell, dropping 0.10% to 4,443.63. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
34 Stocks Moving In Wednesday's Mid-Day Session
Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 139% to $8.18 after surging over 15% on Tuesday. Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 58% to $... 
Via Benzinga
Stocks That Hit 52-Week Highs On Wednesday
Before 10 a.m. ET on Wednesday, 77 companies hit new 52-week highs. Areas of Significance: Pfizer (NYSE:PFE) was the largest firm on a market cap basis to set a new... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Target Reports Upbeat Profit
Following the market opening Wednesday, the Dow traded down 0.12% to 35,300.85 while the NASDAQ rose 0.03% to 14,660.26. The S&P also fell, dropping 0.04% to 4,446.09. The U.S... 
Via Benzinga
Topics Stocks
Exposures US Equities
22 Stocks Moving in Wednesday's Pre-Market Session
Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares rose 50.6% to $23.12 in pre-market trading. Virpax Pharmaceuticals shares jumped 265% on Tuesday after the company... 
Via Benzinga
Why Virpax Pharmaceuticals Shares Are Soaring Today
Virpax Pharmaceuticals Inc (NASDAQ: VRPX) is surging higher Tuesday after the company announced that it received a written pre-investigational new drug response from the... 
Via Benzinga
Mid-Afternoon Market Update: Dow Tumbles Over 400 Points; Virpax Pharmaceuticals Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 1.18% to 35,204.03 while the NASDAQ fell 1.24% to 14,610.77. The S&P also fell, dropping 1.06% to 4,432.01. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
66 Biggest Movers From Yesterday
Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-investigational new drug (pre-IND... 
Via Benzinga
VRPX Stock: 6 Things for Virpax Pharma Investors to Know as Shares Rocket Over 250%
Virpax Pharma (VRPX) stock is rocketing higher on Tuesday after getting a response from the FDA concerning an anti-viral barrier product. 
Via InvestorPlace
Exposures Product Safety
Mid-Day Market Update: monday.com Jumps Following Strong Q2 Results; Kubient Shares Plunge
Midway through trading Tuesday, the Dow traded down 0.81% to 35,336.88 while the NASDAQ fell 0.89% to 14,661.86. The S&P also fell, dropping 0.65% to 4,450.54. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
48 Stocks Moving In Tuesday's Mid-Day Session
Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares jumped 93% to $$8.10 after the company received a written pre-investigational new drug (pre-IND) response from the FDA... 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; Walmart Profit Tops Estimates
Following the market opening Tuesday, the Dow traded down 0.67% to 35,385.44 while the NASDAQ fell 0.79% to 14,676.74. The S&P also fell, dropping 0.54% to 4,455.32. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 55 companies set new 52-week highs. Points of Interest: Apple (NASDAQ:AAPL) was the largest company by market cap to set a new 52-week... 
Via Benzinga
Why Virpax Pharmaceuticals Stock Flying Higher?
Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019. The drug candidate... 
Via Benzinga
Exposures Product Safety
Virpax® Pharmaceuticals Receives FDA Response and Guidance on MMS019
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.